News Breaks |
|
|
| January 26, 2013 |
| 16:11 EDT |  | ACT, TEVA, ENDP, COV, ABT | FDA panel recommends new restrictions on painkiller, WSJ says
After two days of testimony, an FDA drug safety advisory panel voted 19-10 to recommended new restrictions on products containing hydrocodone—a category that includes Vicodin--should be reclassified as Schedule II controlled substances, along with other narcotic painkillers such as oxycodone, says the Wall Steet Journal. Hydrocodone products are currently in Schedule III. Reference Link |
|
|
News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days Check below for free stories on ACT;TEVA;ENDP;COV;ABT the last two weeks. |
|
|
| May 17, 2013 |
| 11:53 EDT |  | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 16, 2013 |
| 10:03 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:27 EDT | | ENDP | Endo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. |
|
| 08:11 EDT |  | ACT | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| 07:46 EDT |  | ACT | Jefferies sees high probability of Actavis, Warner Chilcott merger
Jefferies believes a takeover of Warner Chilcott (WCRX) by Actavis (ACT) would make strategic and financial sense and would be significantly accretive to Actavis. The firm sees a high probability of a deal getting done and raised its price target for Actavis to $120 from $81 while keeping a Hold rating on the name. Jefferies estimates a deal at $24 per Warner Chilcott share would be accretive to Actavis' 2014 earnings by $5.31. |
|
| 07:28 EDT |  | COV | I/O Central to host a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | ACT | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | ACT | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| 07:03 EDT | | ACT | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | ACT | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
| |
| 13:36 EDT | | ACT | Actavis discussing over $5B bid for Warner Chilcott, Bloomberg reports
Bloomberg cites a source. |
|
| 13:22 EDT | | ACT | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| 07:18 EDT | | ACT | BofA/Merrill to host a conference
2013 Health Care Conference is being held in Las Vegas on May 14-16. |
|
| May 13, 2013 |
| 12:14 EDT | | ACT | Actavis price target raised to $140 from $125 at Buckingham
Subscribe for More Information |
|
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 09:27 EDT |  | ENDP | Endo Health downgraded to Market Perform from Outperform at William Blair
|
|
| 09:25 EDT | | ENDP | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:04 EDT | | ACT | Actavis NDA for progestin-only patch accepted for filing by FDA
Subscribe for More Information |
|
| 09:04 EDT |  | ENDP | Endo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30 |
|
| 09:00 EDT | | ACT | Warner Chilcott price target raised to $21 from $18 at Susquehanna
Susquehanna raised its price target on Warner Chilcott (WCRX) following its confirmation it is in discussions with Actavis (ACT) about a business combination. The firm believes the possible combination is compelling and worth exploring. Shares are Positive rated. |
| |
|
|
|
|
